This comprehensive encyclopedic reference provides rapid access to focused information on topics of cancer research for clinicians, research scientists and advanced students. Given the overwhelming success of the first edition, which appeared in 2001, and fast development in the different fields of cancer research, it has been decided to publish a second fully revised and expanded edition. With an A-Z format of over 7,000 entries, more than 1,000 contributing authors provide a complete reference to cancer. The merging of different basic and clinical scientific disciplines towards the common goal of fighting cancer makes such a comprehensive reference source all the more timely.

Cancer and Noncoding RNAs offers an in-depth exploration of noncoding RNAs and their role in epigenetic regulation of complex human disease, most notably cancer. In addition to examining microRNAs, this volume provides a unique evaluation of more recently profiled noncoding RNAs now implicated in carcinogenesis, including lncRNAs, piRNAs, circRNAs, and tRNAs, identifying differences in function between these noncoding RNAs and how they interact with the rest of the epigenome. A broad range of chapters from experts in the field detail epigenetic regulation of various cancer types, along with recent next generation sequencing technologies, genome-wide association studies (GWAS) and bioinformatics approaches. This book will help researchers in genomic medicine and cancer biology better understand the role of noncoding RNAs in epigenetics, aiding in the development of useful biomarkers for diagnosis, prognosis and new RNA-based disease therapies. - Provides a comprehensive analysis of noncoding RNAs implicated in epigenetic regulation of gene expression and chromatin dynamics - Educates researchers and graduate students by highlighting, in addition to miRNAs, a range of noncoding RNAs newly associated with carcinogenesis - Applies current knowledge of noncoding RNAs and epigenomics towards developing cancer and RNA-based disease therapies - Features contributions by leading experts in the field

Epigenetic Cancer Therapy unites issues central to a translational audience actively seeking to understand the topic. It is ideal for cancer specialists, including oncologists and clinicians, but also provides valuable information for researchers, academics, students, governments, and decision-makers in the healthcare sector. The text covers the basic background of the epigenome, aberrant epigenetics, and its potential as a target for cancer therapy, and includes individual chapters on the state of epigenome knowledge in specific cancers (including lung, breast, prostate, liver). The book encompasses both large-scale intergovernmental initiatives as well as recent findings across cancer stem cells, rational drug design, clinical trials, and chemopreventative strategies. As a whole, the work articulates and raises the profile of epigenetics as a therapeutic option in the future management of cancer. - Concisely summarizes the therapeutic implications of recent, large-scale epigenome studies, including the cancer epigenome atlas - Discusses targeted isoform specific versus pan-specific inhibitors, a rational drug design approach to epigenetics relevant to pharmacoepigenetic clinical applications - Covers new findings in the interplay between cancer stem cells (CSCs) and drug resistance, demonstrating that epigenetic machinery is a candidate target for the eradication of these CSCs

The purpose of this volume is to review and discuss key growth factor systems that have been implicated in embryogenesis. Emphasis is placed on the insulin family of peptides, including insulin and the structurally and functionally related insulin-like growth factors. The initial chapters provide a review of basic topics, including developmental genetics, energy metabolism and hormonal signaling mechanisms, which are important prerequisites to the central theme that follows. The book concludes with a brief review of oncogene expression in early development; this new field has contributed significantly to our understanding of how mitogenic signals activate genetic elements responsible for embryonic growth and development. This book presents information important to cell biologists, endocrinologists, biological chemists, and developmental biologists.

Now available in a fully updated third edition, Equine Ophthalmology is the most comprehensive and current clinical resource for the diagnosis and treatment of ophthalmic disease in horses. Provides complete, authoritative information on the diagnosis and treatment of ophthalmic disease in horses Fully updated with improved figures, the latest research, and new chapters on advanced diagnostics, foal ophthalmology, neuro-ophthalmology, national and international regulations, and an expanded chapter on inherited ocular disease Features contributions from an international group of equine experts, under the editorship of a leading equine veterinary specialist Offers comprehensive coverage of clinical and reference information ideal for specialists, general equine practitioners, and veterinary students alike Includes access to a companion website with expanded content and figures

Scientific Frontiers in Developmental Toxicology and Risk Assessment reviews advances made during the last 10-15 years in fields such as developmental biology, molecular biology, and genetics. It describes a novel approach for how these advances might be used in combination with existing methodologies to further the understanding of mechanisms of developmental toxicity, to improve the assessment of chemicals for their ability to cause developmental toxicity, and to improve risk assessment for developmental defects. For example, based on the recent advances, even the smallest, simplest laboratory animals such as the fruit fly, roundworm, and zebrafish might be able to serve as developmental toxicological models for human biological systems. Use of such organisms might allow for rapid and inexpensive testing of large numbers of chemicals for their potential to cause developmental toxicity; presently, there are little or no developmental toxicity data available for the majority of natural and manufactured chemicals in use. This new approach to developmental toxicology and risk assessment will require simultaneous research on several fronts by experts from multiple scientific disciplines, including developmental toxicologists, developmental biologists, geneticists, epidemiologists, and biostatisticians.

Because of the recent advances in embryo modeling techniques, and at the request of the Office of Science Policy in the Office of the Director at the National Institutes of Health, the National Academies of Sciences, Engineering, hosted a 1-day public workshop that would explore the state of the science of mammalian embryo model systems. The workshop, which took place on January 17, 2020, featured a combination of presentations, panels, and general discussions, during which panelists and participants offered a broad range of perspectives. Participants considered whether embryo model systems - especially those that use nonhuman primate cells - can be used to predict the function of systems made with human cells. Presentations provided an overview of the current state of the science of in vitro development of human trophoblast. This publication summarizes the presentation and discussion of the workshop.